Skip to main content
OpenTrials

Clinical trial condition

Myelofibrosis

Explore clinical trials studying Myelofibrosis. Study availability and eligibility vary by location and protocol.

175 public trials 45 recruiting studies
Refine in advanced search Browse all conditions

Myelofibrosis trial results

Active, not recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414

Conditions
Anemia, Bone Marrow Diseases, Hematologic Diseases, +5 more
Locations
  • Local Institution - 110 Los Angeles, California, United States
  • Local Institution - 135 Orlando, Florida, United States
  • Local Institution - 133 Plantation, Florida, United States
  • Local Institution - 112 Chicago, Illinois, United States
View all 185 locations
View Trial Details
Active, not recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156

Conditions
Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, +6 more
Locations
  • University of California-San Diego/Moores UCSD Cancer Center La Jolla, California, United States
  • UCLA David Geffen School of Medicine Los Angeles, California, United States
  • Smilow Cancer Center at YNHH New Haven, Connecticut, United States
  • BRCR Medical Center Inc Plantation, Florida, United States
View all 144 locations
View Trial Details
Active, not recruiting

Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

NCT04217356

Conditions
Bone Marrow Cancer, Bone Marrow Diseases, Bone Marrow Neoplasms, +9 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • St. Paul's Hospital Vancouver, British Columbia, Canada
  • Nova Scotia Health Authority Halifax, Nova Scotia, Canada
View Trial Details
Active, not recruiting

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • The Oncology Institute of Hope and Innovation Pasadena, California, United States
  • Rocky Mountain Cancer Centers, LLP Aurora, Colorado, United States
  • Illinois Cancer Specialist Niles, Illinois, United States
  • Texas Oncology - Northeast Texas Tyler, Texas, United States
View all 21 locations
View Trial Details
Active, not recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT03289910

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, +32 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Oncology/Hematology-Newport Beach Newport Beach, California, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Active, not recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • Local Institution - 0069 Newport Beach, California, United States
  • Local Institution - 0090 Lake Mary, Florida, United States
  • Local Institution - 0043 New Orleans, Louisiana, United States
  • Local Institution - 0038 Worcester, Massachusetts, United States
View all 49 locations
View Trial Details
Active, not recruiting

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

NCT03069326

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
  • Memorial Sloan Kettering Westchester Harrison, New York, United States
View Trial Details
Active, not recruiting

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • UAB Division of Hematology/Oncology Birmingham, Alabama, United States
  • UCLA - Satellite Site Beverly Hills, California, United States
  • City of Hope Duarte, California, United States
  • UCLA - Satellite Site Encino, California, United States
View all 166 locations
View Trial Details
Active, not recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +19 more
Locations
  • University of Alabama At Birmingham Birmingham, Alabama, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Emory University-Winship Cancer Institute Atlanta, Georgia, United States
View all 48 locations
View Trial Details

Related conditions